Pharmaceutical giant Moderna has signed a memorandum of understanding (MOU) with Kenya’s government for its first mRNA vaccine manufacturing facility in Africa.
In a statement on Monday (07 March), the company said its goal is to produce up to 500 million doses of vaccines a year for the continent, with a focus on drug substance manufacturing, though the facility could be expanded to include fill-and-finish work.
“In parallel, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand,” the company said.
Pharmaceutical giant Moderna has signed a memorandum of understanding (MOU) with Kenya’s government for its first mRNA vaccine manufacturing facility in Africa.
In a statement on Monday (07 March), the company said its goal is to produce up to 500 million doses of vaccines a year for the continent, with a focus on drug substance manufacturing, though the facility could be expanded to include fill-and-finish work.
“In parallel, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand,” the company said.
